Drug shortages continue to put patients at risk, threatening access to lifesaving cancer treatments and creating uncertainty for healthcare providers who are often forced to make urgent, real-time decisions about patient care.

The New York Times recently reported on ongoing shortages of critical chemotherapy medications, including widely used generic oncology drugs that form the backbone of many cancer treatment regimens. These medicines are often produced by a small number of manufacturers, and even minor disruptions in production or supply can quickly ripple through the healthcare system, leading to constrained availability at the patient level.

In a recent interview with The New York Times, Angels for Change Founder & Chief Change Maker Laura Bray called for meaningful action to address the root causes of these ongoing shortages:

““From a systemwide policy change, not a single thing has changed. It’s time for Washington to get involved and help the citizens of the United States ensure that we have lifesaving medicine.””

While collaborative efforts across the healthcare ecosystem are helping to mitigate the impact of shortages in real time, long-term solutions will require sustained policy action, investment, and a shared commitment to strengthening the pharmaceutical supply chain.

We remain committed to advancing solutions that strengthen the pharmaceutical supply chain and ensure every patient has access to the medicines they need. Our drug shortage hotline is supporting patients. Thank you to all of our partners who help ensure patients continue to receive care during disruption.

Shortage of Chemotherapy Drugs Brings Rationing Fears

Doctors are contending with low supplies and unfiled orders of generic chemotherapy infusions that are central to the treatment of a long list of cancers.

🔗 Read The New York Times Article here or by clicking the button below: https://bit.ly/4uZng2H

Source: Jewett, C. (2026, June 24). Chemotherapy Drug Shortage Raises Rationing Fears. The New York Times.